Impetigo (Video 2:28 minutes)

Article

Impetigo has lots of mimics. Ted Rosen, MD, describes the diagnostic contenders and the treatments that can cure the infection in an era of increasing mupirocin resistance.

Impetigo has lots of mimics. Ted Rosen, MD, describes the diagnostic contenders and the treatments that can cure the infection in an era of increasing mupirocin resistance.

For more webinar videos, click here.

Recent Videos
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Discussion: AAP's opioid for acute pain clinical practice guideline with Jessica Spruit, DNP
Bobbie Monaco, MSN, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
Do probiotics reduce allergy symptoms? It’s complicated! | Image credit: Contemporary Pediatrics

Do probiotics reduce allergy symptoms? It’s complicated!

Marian Freedman;Jon Matthew Farber, MD
April 21st 2025
Article

In 3 studies evaluating the effects of probiotics on eczema, probiotics groups reported a greater reduction in symptoms than placebo groups, but only when the allergy was IgE mediated.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA issues CRL for aflibercept 8 mg extended dosing for all indications | Image Credit: © Araki Illustrations - stock.adobe.com.

FDA issues CRL for aflibercept 8 mg extended dosing for all indications

Joshua Fitch, Senior Editor
April 18th 2025
Article

The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

Joshua Fitch, Senior Editor
April 18th 2025
Article

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

Image Credit: © John Doe - © John Doe - stock.adobe.com.

Viral studies reduce antibiotic use in hospitalized febrile infants

Marian Freedman;Jon Matthew Farber, MD
April 17th 2025
Article

"Testing for viruses should be the standard of care to help guide therapy," stated Jon Matthew Farber, MD.

© 2025 MJH Life Sciences

All rights reserved.